Ischemic Optic Neuropathy in Male Veterans Prescribed Phosphodiesterase-5 Inhibitors - 21/08/11
, Dustin D. French, PhD b
Inquires to Curtis E. Margo, MD, MPH, Department of Pathology, University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 11, Tampa, FL 33612Résumé |
Purpose |
To determine the feasibility of a case-control study of phosphodiesterase (PDE)-5 inhibitors and nonarteritic ischemic optic neuropathy (NION).
Design |
Retrospective cohort study using the National Veterans Health Administration’s pharmacy and clinical databases.
Methods |
setting: National database. patient population: Male veterans 50 years of age and older with newly diagnosed NION or “possible” NION. interventional procedure: Dispensed prescription for a PDE-5 inhibitor. outcome measure: Incidence of NION and “possible” NION based on exposure to PDE-5 inhibitors.
Results |
The relative risk of NION among men prescribed a PDE-5 inhibitor was 1.02 (95% confidence interval [CI]: 0.92 to 1.12). The relative risk of possible NION among men prescribed a PDE-5 inhibitor was 1.34 (95% CI: 1.17 to 1.55).
Conclusions |
The collective risk of NION and possible NION was marginally significant (relative risk [RR] 1.10 95% CI: 1.02 to 1.20). A case-control study, in which the dependent variable is NION and the effect size of the PDE-5 inhibitor is assumed small, is feasible.
Le texte complet de cet article est disponible en PDF.
Vol 143 - N° 3
P. 538-539 - mars 2007 Retour au numéro
Article précédent
- Two Patients With the von Szily Reaction: Herpetic Keratitis and Contralateral Retinal Necrosis
- Lynnelle K. Smith, Paul A. Kurz, David J. Wilson, Christina J. Flaxel, James T. Rosenbaum
- Accommodative Spasm after Laser-Assisted In Situ Keratomileusis (LASIK)
- Gaurav Prakash, Namrata Sharma, Preeti Sharma, Vandana Choudhary, Jeewan S. Titiyal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?